Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.

< BACK TO ARCHIVE


Papers: 20 Mar 2021 - 26 Mar 2021


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Mar 25


Headache


http://www.ncbi.nlm.nih.gov/pubmed/33764538?dopt=Abstract

Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.

Authors

Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD
Headache. 2021 Mar 25.
PMID: 33764538.

Abstract

To assess long-term (up to 2 years) efficacy, tolerability, and safety of erenumab for the prevention of episodic migraine (EM) in Japanese patients.
Read This Paper